Myriad Genetics Showcases Promising MRD Test Data at ASCO 2026
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Image: Benzinga
At the 2026 ASCO Annual Meeting, Myriad Genetics presented data on its Precise MRD test, highlighting its effectiveness in detecting molecular residual disease across various cancer types. The findings from the MONSTAR-SCREEN-3 study indicate that the test can significantly predict disease recurrence, enhancing clinical decision-making.
- 01The MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, demonstrated a 97% baseline detection rate using the Precise MRD test.
- 02Patients with detectable circulating tumor DNA (ctDNA) post-surgery showed significantly worse disease-free survival, indicating the test's prognostic value.
- 03Myriad's Precise MRD test is designed to monitor ctDNA levels throughout a patient's cancer treatment journey.
- 04The study involved over 1,100 patients and utilized whole-genome sequencing to personalize the MRD assessment.
- 05Myriad Genetics aims to establish a new standard in oncology with ultra-sensitive detection methods.
Advertisement
In-Article Ad
Myriad Genetics, a leader in molecular diagnostics, presented compelling data at the 2026 ASCO Annual Meeting regarding its Precise MRD (molecular residual disease) test. The test's efficacy was highlighted through six poster presentations, particularly the interim results from the MONSTAR-SCREEN-3 study, which involved over 1,100 patients undergoing treatment for various solid tumors. Dr. Takayuki Yoshino reported that the test achieved a 97% baseline detection rate, with 16% of samples detected at ultrasensitive levels. Notably, patients who tested positive for circulating tumor DNA (ctDNA) one month after surgery faced a significantly higher risk of recurrence, underscoring the test's potential to inform treatment decisions. Myriad's Chief Scientific Officer, Dale Muzzey, emphasized the importance of sensitive detection in improving clinical outcomes. The conference also featured discussions on the test's application in multiple cancer types, including ovarian and gastric cancers. Myriad Genetics aims to set a new benchmark in cancer care through this innovative approach, which could revolutionize how oncologists monitor and respond to disease progression.
Advertisement
In-Article Ad
The Precise MRD test could significantly improve cancer monitoring and treatment strategies, leading to better patient outcomes.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the advancements in cancer diagnostics presented at ASCO 2026?
Connecting to poll...
Read the original article
Visit the source for the complete story.




